Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SuMR: upfront sunitinib followed by surgery in metastatic renal cancer
2006-004511-21Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC), sponsored by Queen Mary University of London. Primary endpoint: Time to radiological progression. Started Mar 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2006-004511-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004511-21.